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Bogovoski & E A Walker. Scientific Publications No. 9, IARC, Lyon; Miss C M Evans (Urology Department, Nottingham City Hospital, Nottingham, NG5 IPB) and Dr J G Bowen (Cancer Research Campaign Laboratories, Nottingham University, Nottingham, NG7 2RD) Immunological Tests in Carcinoma of the Prostate It has been well established that in animal tumour systems, the tumours carry antigens which are immunogenic in the autochthonous host (Baldwin 1973 , Basombrio & Prehn 1972 , Hellstr6m & Hellstrom 1969 . In man, however, the evidence is more circumstantial and age distribution of tumours, for example, has been cited as being indicative of an immune surveillance mechanism, as has the higher incidence of tumours in immunosupressed or immunodeficient patients. The fact that there appears to be a correlation between lymphoid cell infiltration into the tumour, and prognosis has also been interpreted as showing the existence of an immune response directed against the tumour. In vitro evidence for the existence of an ongoing immune response, particularly in terms of the cytotoxicity of lymphoid cells for cultured tumour cells, is currently an area of much controversy (Baldwin 1975 , Herberman & Oldham 1975 , although other systems such as leukocyte migration testing (Char et al. 1973 , Cochran et al. 1974 , Black et al. 1974a , Black et al. 1974b or leukocyte adherence inhibition testing (Halliday et al. 1974 have suggested the existence of antigens which crossreact between tumours of the same histological type but not with tumours which arise in other tissues. These latter two tests have shown that reactivity is present in melanoma, breast and colorectal carcinoma patients. However, in patients with a heavy tumour load, i.e. Stage IV tumour, reactivity can be depressed. For example, with the leukocyte migration (LM) test, Black et al. (1974a) , examining mammary carcinoma, and
Elizas & Elias (1975) , with colorectal carcinoma patients, concluded that the lower the staging the greater the percentage of patients who were capable of reacting to homologous tumour tissue.
Similarly, examined melanoma patients using the leukocyte adherence inhibition (LAI) test and showed that 80 % of these patients could react against a melanoma extract whereas only 4.5 % of healthy donors responded against the same extract. They also showed that the response was decreased for a short period following surgery in patients with disseminated melanoma or in patients being treated by cytotoxic drugs. Furthermore, they concluded that residual or recurrent tumour caused a persistent or recurrent LAI reactivity, results which are similar to those of O' Toole et al. (1973) who maintained that the reappearance of lymphocytes cytotoxic for the bladder tumour cell line T24 indicated the recurrence of tumour.
Delayed dermal hypersensitivity has been used by a number of investigators to examine the in vivo immunological response of cancer patients. The results using recall antigens such as paraphenylenediamine (PPD) (Thomas et al. 1976 ), primary reactive antigens e.g. dinitrochlorobenzene (DNCB) (Simo-Camps et al. 1976 ) or homologous tumour extracts (Oren & Herberman 1971) have been rather disappointing in terms of determining a patient's prognosis, the major correlation being with a patient's age (Gross 1965 ). However, although poor reactivity has been detected in a group of morbid patients in the terminal stages of disease good reactivity is not found in patients with minimal disease. In general, these tests have proven uninformative when applied at the individual patient level.
On the hypothesis that two tests may give more information than either alone, a pilot study was begun using patients with prostatic cancer who were examined by the leukocyte migration test or the leukocyte adherence inhibition test and by dinitrochlorobenzene delayed dermal hypersensitivity testing.
Materials and Methods
Heparinized blood samples were obtained from patients attending the City Hospital, Nottingham. Diagnosis of prostatic carcinoma was confirmed histologically from biopsy specimens during transurethral resection of the prostatic mass and patients were staged according to the Veterans Administration Cooperative Urological Research Group (VACURG) system (1967) . Control blood was obtained from a variety of age and sexmatched hospital patients undergoing treatment for nonmalignant disease as well as from a panel of male laboratory workers. Antigen extract preparation: Tissue obtained during transurethral resection of a prostatic mass was classed on the basis of histology by an experienced pathologist as prostatic carcinoma (PC) or benign prostatic hypertrophy (BPH). Both tissues were treated identically by vigorous homogenization in phosphate buffered saline (pH 7.3) and centrifuged at 20 000 g for 1 hour to remove unbroken cells and large debris. The supernatant was collected and protein concentration determined and used after suitable dilution in phosphate buffered saline in the in vitro immunological tests. Preparation of leukocytes: This was performed according to the method of Cochran et al. (1974) . Peripheral blood (20 ml) containing 1000 iu of preservative free heparin was allowed to stand at 37°C for 45 min and the leukocyte rich plasma collected. Leukocytes were isolated from the plasma by gentle centrifugation, treated with trisbuffered NH4C 1 solution for 15 min at room temperature to lyse contaminating erythrocytes and, following two further washes in the medium relevant to the particular test, counted and used in that test. Leukocyte migration test (LM): Leukocytes were washed in bicarbonate-buffered Eagle's minimum essential medium (MEM) supplemented with 10 % fetal calf serum (FCS). The cells were then resuspended in ten times their own volume of Eagle's MEM plus 100% FCS and 200 pl aliquots of this suspension were placed in x 65 mm glass test tubes and the appropriate amount of antigen added in 200 ,ul phosphate buffered saline. After 2 hours at 37°C, the suspension was centrifuged 200 g for 10 min and the cell pellet resuspended in 200 pl Eagle's MEM + 10 % FCS. Three capillary tubes were filled with the suspension, sealed with inert clay and centrifuged at 200 g for 10 min. The tubes were cut at the cell-fluid interphase and the portions containing the cell-button were mounted in disposable migration plates. Eagle's MEM + 10 % FCS was added to fill the chambers which were sealed with a clean coverslip. The plates were incubated in a humidified chamber at 37°C for 36 hours and then the areas of migration measured with a planimeter. The migration index was calculated by dividing the area of migration of cells treated with PC extract by the area of migration of cells treated with BPH extract at the same protein concentration. The limits for a significant effect on the migration of leukocytes were taken as 1+ 2 standard deviations using control healthy donor leukocytes as the baseline so that migration indices of less than 0.8 and greater than 1.2 were taken as significant. Leukocyte adherence inhibition test (LAI): This was carried out by the method of . Leukocytes were washed twice in Eagle's MEM supplemented with 20 mmol/l HEPES and 33 mg/100 ml sodium bicarbonate and without FCS. The cells were resuspended to 107 leukocytes/ml and 100 gl of this suspension added to 16 x 90 mm pyrex test tubes containing 300 l medium and 100 tl of tissue extract at the required concentration. The contents of the tube were then mixed and the tubes laid on their sides in a humidifed chamber containing an atmosphere of 5 % CO2 and incubated at 37°C. After 2 hours the tubes were stood upright and the nonadherent cells gently resuspended and counted. The nonadherence index (NAI) was calculated according to the formula: Significance levels were taken as the mean NAI plus 2 standard deviations using control healthy donor leukocytes. Values of 53 or greater were therefore denoted as indicating significant inhibition of adherence. Dinitrochlorobenzene (DNCB) delayed hypersensitivity test: The method used was a modification of that described by Bolton (1975) . The sensitization dose of 0.1 ml of 20% DNCB in acetone was applied to the left forearm. Two weeks later, the test dose of 0.1 ml of 0.50% DNCB in acetone was applied to the right forearm and after 48 hours the response was read. The test was considered positive only if there was erythema and induration.
Results
Results obtained using the leukocyte migration test are shown in Table 1 . Although it appears that there may be fewer individuals reactive against the PC extract in the group of patients with Stage I and II disease (3/6) when compared to the Stage IV patients (5/5) the difference is not significant. This may be a reflection of the small numbers of patients so far tested and the trend may be Greatly raised * Migration indices of less than 0.8 and greater than 1.2 were taken as significant * Treatment with cestrogens or orchidectomy substantiated when greater numbers have been tested. There is no apparent correlation with tumour staging or other clinical parameters of tumour load measurement. The results do show however that there is a different pattern of reactivity of leukocytes from patients with prostatic carcinoma against benign prostatic carcinoma tissue homogenate than against prostatic hypertrophy tissue and that this reactivity appears to be absent in healthy age and sex-matched controls ( Table 3) .
The leukocyte adherence inhibition test shows essentially the same pattern of reactivity as does the leukocyte migration test (Tables 2 & 3) . There is no apparent correlation between reactivity and tumour staging by clinical criteria and the acid phosphatase levels can again be dissociated from the leukocyte adherence inhibition activity. It may be noted, however, that treatment of the patient with cytotoxic drugs does not abolish leukocyte reactivity in this test. CF and EW were tested twice in this system, using blood samples taken at one month intervals, and gave similar results on each occasion. The test, therefore, probably detects a real event. Furthermore, there appears to be a good correlation between LM and LAI reactivity since 3 patients, WCr, AA and EW were tested on the same day in both systems and gave identical results. Stage  I   II   II   II   IV   IV   IV   IV   IV   IV   IV   IV   IV   IV   IV   IV   IV The LAI test appears to be more sensitive in detecting reactivity to the PC homogenate than does the LM test since 17 of the 19 patients reacted on the former test and only 8 out of 11 patients in the latter test (Table 3 ). Reactivity of healthy controls are essentially similar in both tests but there appears to be a greater degree of crossreactivity with BPH patients in the leukocyte migration test although the numbers are too small for statistical analysis.
Eighteen patients were tested for delayed dermal hypersensitivity responses to DNCB. Patients with Stage I and II tumour react to the challenge dose of DNCB better than do Stage IV patients, 4 from 5 as opposed to 6 from 13 respectively. Thus, patients with a small tumour load appear to have a better response.
Discussion
On the basis of the limited number of patients so far tested, it is apparent that there is a high level of response of leukocytes from prostatic carcinoma patients against the prostatic carcinoma extract when compared with leukocytes from healthy, age and sex-matched or benign prostatic hypertrophy controls, in both the leukocyte migration test (Table 1 ) and the leukocyte adherence inhibition test (Table 2 ). This indicates that there is some form of cancer-related specificity (Table 3) , although the precise tumour specificity of the reaction is not yet known although currently under investigation. The test is reproducible, since 3 patients were tested in both leukocyte migration and leukocyte adherence inhibition tests and gave parallel results. Also, 2 patients were tested again after a one month interval and reacted similarly on both occasions.
There appears to be little influence of tumour staging of the leukocyte donors in the leukocyte migration test although the numbers tested are rather small. The patients in the leukocyte adherence inhibition test were primarily of Stage IV disease level but there is still a high level of reactivity, in fact patient EW who was reactive in both test systems died within two weeks of the last test. These results do not agree with data obtained in other tumour systems. For example, in mammary cancer patients tested using the leukocyte migration test Cochran et al. (1974) . Elias & Elias (1975) found in patients with colorectal tumours that leukocyte migration reactivity was decreased in the presence of a heavy tumour load. In a melanoma system, and Halliday et al. (1975) showed that leukocytes from patients with early malignant melanoma reacted in the leukocyte adherence inhibition test to a much greater extent than leukocytes from patients with disseminated disease. These results have been repeated using the same test system in patients with mammary cancer (Grosser & Thomson 1975) . It is unlikely that prostatic carcinoma is different to the other tumour systems since Thomas et al. (1976) have shown that prostatic carcinoma patients are anergic to DNCB and our results show that Stage IV patients are less reactive than Stage I and II in the DNCB delayed hypersensitivity test, results comparable to those obtained in other tumour systems (Bolton 1975 ).
One of the major points of interest is that treatment of Stage IV prostatic carcinoma patients with cytotoxic drugs, such as 5-flourouracil, does not appear to abrogate the leukocyte adherence inhibition response which correlates with the passive reaction mechanism proposed by rather than the active mechanism suggested by .
The original aim of the work was to examine the possibility of immunological testing of prostatic carcinoma patients being used in determining prognosis. The present results suggest that there is a correlation between ability to respond to nonspecific antigens e.g. DNCB and the presence of small tumour load. However, the specific tests leukocyte migration and leukocyte adherence inhibition, whilst indicating an ongoing immune response directed towards the tumour give no indication of tumour load and prognosis. Serial measurement of reactivity are being carried out on the patients already tested and it is hoped that these sequential tests and/or more refined techniques may be of value in carcinoma of the prostate.
